Often, cancerous cells produce aberrant DNA molecules which are difficult to detect by normal genome sequencing techniques. Fluorescent In-Situ Hybridization (FISH) is a highly sensitive and specific detection method for identifying these cytogenetic changes. Precision for Medicine (formerly ApoCell) develops state-of-the-art FISH assays to detect abnormalities in both hematological and solid organ tumors.


FISH taking place

Cytogenetic analysis of CTCs often provides information regarding diagnosis, prognosis and therapeutic surveillance of cancer patients.

We have developed DNA FISH assays to cytogenetically analyze CTCs after enrichment from patient whole blood. Isolated cells are first immunophenotyped to identify CTCs and then CTCs are relocated after target-specific FISH analysis has been performed.

  • FISH in CTCs, CECs, FFPE, frozen tissue, and bone
  • Detect cellular genetic aberrations: multiploidy, translocations, amplifications or deletions
  • Custom FISH probe design services
  • Commercially available FISH assays
  • Proprietary disease-specific FISH panels

The markers below are commonly utilized FISH targets; please visit our Test Menu for a more thorough listing.

c-Met EGFR


In addition to examining changes in DNA by FISH, Precision for Medicine is also able to query modifications to RNA targets using ACD’s RNAscope ISH assays and technology. Commercially available or custom RNA ISH targets are available for incorporation into one of our integrated workflows.